RxDoctor Payments Data

Mohannad Azzam, MD

Physical Medicine & Rehabilitation · Hoover, ALNPI 1013141951

Payments from drug & device makers

$233in general payments, 2019–2025

Across 6 payments — averaging $38.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$201
  • Otsuka America Pharmaceutical, Inc.$17
  • Pfizer$15

What the payments were for

  • Food & beverage$233100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis4$201
Otsuka America Pharmaceutical, Inc.1$17
Pfizer1$15

How this compares

$233 in reported general payments places this provider in the 40th percentile of 104 physical medicine & rehabilitation providers in Alabama.

See all physical medicine & rehabilitation providers in Alabama

Medicare billing

Part B allowed, 2024
$1,995,112
Medicare patients
729
Services billed
6,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,284$765,738
IngrezzaValbenazine Tosylate57$240,874
AustedoDeutetrabenazine33$227,768
RexultiBrexpiprazole213$172,483
SantylCollagenase Clostridium Hist.137$165,677
XareltoRivaroxaban286$96,123
JardianceEmpagliflozin268$90,371
JanuviaSitagliptin Phosphate225$83,849
Invega SustennaPaliperidone Palmitate22$73,639
BiktarvyBictegrav/Emtricit/Tenofov Ala17$67,687
NuedextaDextromethorphan Hbr/Quinidine64$65,809
EntrestoSacubitril/Valsartan159$60,449
OtezlaApremilast22$56,033
LinzessLinaclotide93$53,162
Atorvastatin Calcium2,926$45,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$765,7382,284 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$17$214,207227 claims
NovartisEntresto$201$60,449159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 104 physical medicine & rehabilitation providers in Alabama.

Other physical medicine & rehabilitation in Hoover

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →